CELESTONE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Celestone, and what generic alternatives are available?
Celestone is a drug marketed by Schering, Merck Sharp Dohme, and Organon. and is included in five NDAs.
The generic ingredient in CELESTONE is betamethasone acetate; betamethasone sodium phosphate. There are sixty-six drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the betamethasone acetate; betamethasone sodium phosphate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Celestone
A generic version of CELESTONE was approved as betamethasone acetate; betamethasone sodium phosphate by AM REGENT on July 31st, 2009.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CELESTONE?
- What are the global sales for CELESTONE?
- What is Average Wholesale Price for CELESTONE?
Summary for CELESTONE
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 5 |
| Raw Ingredient (Bulk) Api Vendors: | 79 |
| Clinical Trials: | 21 |
| Patent Applications: | 4,314 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for CELESTONE |
| DailyMed Link: | CELESTONE at DailyMed |
Recent Clinical Trials for CELESTONE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Indiana Hand to Shoulder Center | Phase 2 |
| CTM Biomedical | Phase 2 |
| Hamilton Health Sciences Corporation | Phase 4 |
US Patents and Regulatory Information for CELESTONE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Schering | CELESTONE | betamethasone | CREAM;TOPICAL | 014762-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Schering | CELESTONE | betamethasone | TABLET;ORAL | 012657-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Schering | CELESTONE | betamethasone sodium phosphate | INJECTABLE;INJECTION | 017561-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Merck Sharp Dohme | CELESTONE | betamethasone | SYRUP;ORAL | 014215-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CELESTONE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Schering | CELESTONE | betamethasone | CREAM;TOPICAL | 014762-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Schering | CELESTONE | betamethasone | TABLET;ORAL | 012657-003 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Merck Sharp Dohme | CELESTONE | betamethasone | SYRUP;ORAL | 014215-002 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
